<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0167329</article-id>
<article-id pub-id-type="publisher-id">PONE-D-16-21632</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cerebrovascular diseases</subject><subj-group><subject>Stroke</subject><subj-group><subject>Ischemic stroke</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Vascular medicine</subject><subj-group><subject>Stroke</subject><subj-group><subject>Ischemic stroke</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cerebrovascular diseases</subject><subj-group><subject>Stroke</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Vascular medicine</subject><subj-group><subject>Stroke</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Bioenergetics</subject><subj-group><subject>Energy-producing organelles</subject><subj-group><subject>Mitochondria</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular structures and organelles</subject><subj-group><subject>Energy-producing organelles</subject><subj-group><subject>Mitochondria</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Critical care and emergency medicine</subject><subj-group><subject>Reperfusion</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Lipids</subject><subj-group><subject>Fatty acids</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Materials science</subject><subj-group><subject>Materials by structure</subject><subj-group><subject>Mixtures</subject><subj-group><subject>Colloids</subject><subj-group><subject>Emulsions</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Neurochemistry</subject><subj-group><subject>Neurotransmitters</subject><subj-group><subject>Glutamate</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Neurochemistry</subject><subj-group><subject>Neurotransmitters</subject><subj-group><subject>Glutamate</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Intravenous Treatment with a Long-Chain Omega-3 Lipid Emulsion Provides Neuroprotection in a Murine Model of Ischemic Stroke – A Pilot Study</article-title>
<alt-title alt-title-type="running-head">Long-Chain Omega-3 Lipid Emulsion as Acute Treatment of Ischemic Stroke</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Berressem</surname>
<given-names>Dirk</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Koch</surname>
<given-names>Konrad</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Franke</surname>
<given-names>Nicole</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Klein</surname>
<given-names>Jochen</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Eckert</surname>
<given-names>Gunter P.</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Goethe-University of Frankfurt, Department of Pharmacology, Germany</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Justus-Liebig-University Giessen, Institute of Nutritional Sciences, Germany</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Ahmad</surname>
<given-names>Muzamil</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Indian Institute of Integrative Medicine CSIR, INDIA</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>This study was funded by Fresenius Kabi. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple">
<list-item><p><bold>Conceptualization:</bold> GPE DB.</p></list-item>
<list-item><p><bold>Formal analysis:</bold> DB NF KK.</p></list-item>
<list-item><p><bold>Investigation:</bold> GPE DB KK NF.</p></list-item>
<list-item><p><bold>Methodology:</bold> GPE JK KK.</p></list-item>
<list-item><p><bold>Project administration:</bold> DB GPE JK.</p></list-item>
<list-item><p><bold>Resources:</bold> JK KK GPE.</p></list-item>
<list-item><p><bold>Supervision:</bold> GPE KK JK.</p></list-item>
<list-item><p><bold>Validation:</bold> DB KK.</p></list-item>
<list-item><p><bold>Visualization:</bold> DB.</p></list-item>
<list-item><p><bold>Writing – original draft:</bold> DB.</p></list-item>
<list-item><p><bold>Writing – review &amp; editing:</bold> JK GPE KK DB.</p></list-item></list></p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">dberressem@gmx.net</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>11</volume>
<issue>11</issue>
<elocation-id>e0167329</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>5</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>11</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Berressem et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0167329"/>
<abstract>
<p>Single long-chain omega-3 fatty acids (e.g. docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA)) are known for their neuroprotective properties associated with ischemic stroke. This pilot study aimed to test the effectiveness of an acute treatment with a long-chain omega-3 lipid emulsion (Omegaven 10%<sup>®</sup>, OGV) that contains fish oil (DHA 18 mg/ml; EPA 21 mg/ml) and α-tocopherol (0.2 mg/ml) in a transient middle cerebral artery occlusion (MCAO) model of ischemic stroke in mice. For this purpose, female CD-1 mice were anesthetized and subjected to 90 minutes of MCAO. To reflect a clinically relevant situation for an acute treatment, either after induction of stroke or after reperfusion, a single dose of OGV was injected intravenously into the tail vein (5 ml/kg b.w.). A neurological severity score was used to assess motor function and neurological outcome. Stroke-related parameters were determined 24 hours after MCAO. Microdialysis was used to collect samples from extracellular space of the striatum. Mitochondrial function was determined in isolated mitochondria or dissociated brain cells. Inflammation markers were measured in brain homogenate. According to control experiments, neuroprotective effects could be attributed to the long-chain omega-3 content of the emulsion. Intravenous injection of OGV reduced size and severity of stroke, restored mitochondrial function, and prevented excitotoxic glutamate release. Increases of pro-inflammatory markers (COX-2 and IL-6) were attenuated. Neurological severity scoring and neurochemical data demonstrated that acute OGV treatment shortly after induction of stroke was most efficient and able to improve short-term neurological outcome, reflecting the importance of an acute treatment to improve the outcome. Summarising, acute treatment of stroke with a single intravenous dose of OGV provided strong neuroprotective effects and was most effective when given immediately after onset of ischemia. As OGV is an approved fishoil emulsion for parenteral nutrition in humans, our results may provide first translational data for a possible early management of ischemic stroke with administration of OGV to prevent further brain damage.</p>
</abstract>
<funding-group>
<funding-statement>This study was partly supported by Fresenius Kabi Deutschland GmbH, Bad Homburg, Deutschland. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="1"/>
<page-count count="18"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Ischemic stroke is a major cause of death worldwide and responsible for serious long-time disability in adults. Thrombolytic treatment provides benefits but only for a small subset of patients who are suitable for lysis therapy. Neuroprotective treatments are aimed at preserving neurons and preventing neurodegeneration but have not been proven effective in humans yet.[<xref ref-type="bibr" rid="pone.0167329.ref001">1</xref>] However, neuroprotection remains a prominent goal for stroke therapy and ischemia-related damage.[<xref ref-type="bibr" rid="pone.0167329.ref002">2</xref>] Ischemia induces changes in mitochondrial respiration and increased mitochondria-related oxidative stress.[<xref ref-type="bibr" rid="pone.0167329.ref003">3</xref>] Thus, mitochondria are an important target for neuroprotection in ischemic stroke.[<xref ref-type="bibr" rid="pone.0167329.ref004">4</xref>] Experimental studies identified intravenous administration of the long-chain omega-3 fatty acid docosahexaenoic acid (DHA)—a major component of fish oil—at least in the next 3 hours following initiation of stroke and 1 hour post-reperfusion as a potent neuroprotective agent in ischemic stroke.[<xref ref-type="bibr" rid="pone.0167329.ref005">5</xref>] It was concluded that DHA has the potential for treating focal ischemic stroke in a clinical setting and that acute administration of DHA enriched lipid emulsions may be an effective intervention in pathogenesis of human stroke.[<xref ref-type="bibr" rid="pone.0167329.ref006">6</xref>] Early discovery and prevention of long-term sequelae is the primary task in treating patients with acute ischemic stroke.[<xref ref-type="bibr" rid="pone.0167329.ref007">7</xref>] Therefore, we aimed to test the effectiveness of an intravenous injection (5 ml/kg b.w.) of OGV shortly after onset of ischemic stroke or after reperfusion in a transient MCAO mouse model. This situation should reflect two clinically relevant points in time or situations: First, an early neuroprotective treatment in patients arriving at the hospital with a suspected ischemic stroke (at stroke). Secondly, a neuroprotective treatment in patients with diagnosed ischemic stroke after lysis or removal of the thrombus (at reperfusion). The quantity of OGV used in this study corresponds to a human dose of 0.41 ml/kg.[<xref ref-type="bibr" rid="pone.0167329.ref008">8</xref>] This dose is in the lower range for human use because OGV is approved for doses up to 2 mL/kg body weight. OGV is an iso-osmolar lipid emulsion already in clinical use for parenteral nutrition and contains fish oil (DHA 18 mg/ml; EPA 21 mg/ml) and α-tocopherol (0.2 mg/ml). We decided to use OGV in a transient MCAO mouse model because our findings would be transferable to a clinical setting, giving a potentially translational outcome. In comparison, earlier studies used free DHA dissolved in saline which is less suitable for the intended human use.[<xref ref-type="bibr" rid="pone.0167329.ref009">9</xref>–<xref ref-type="bibr" rid="pone.0167329.ref011">11</xref>] Stroke related parameters were investigated 24 hours after reperfusion and showed reduced infarct size and infarct severity, improved neurological outcome and behavior, improved mitochondrial function, enhanced glucose levels, prevention of excitotoxic glutamate release and decreased neuroinflammation.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec003">
<title>Animals and experimental stroke model</title>
<p>Female CD-1 mice (27-29g) were purchased from Charles River (Sulzbach, Germany) and kept under standardized conditions: 12 h light/dark cycle, temperature (22°C), humidity (70%) and access to food and water <italic>ad libitum</italic>. All animal procedures were carried out in order to minimize animal suffering according to German and European law. This study was registered and approved by local authorities (Regierungspräsidium Darmstadt, Antrag F8/21) and performed by experienced persons with adequate training conforming to the requirements of the Federation of European Laboratory Animal Science Associations and the European Communities Council Directive (Directive 2010/63/EU). Omegaven 10%<sup>®</sup> (Lot. 16GH0062, containing 18.1 mg/mL DHA and 21.3 mg/mL EPA) was provided by Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany.</p>
<p>Transient in vivo-ischemia was provoked by occluding the middle cerebral artery (MCAO) in the left hemisphere of mice. Mice were anesthetized with isoflurane (Forene<sup>®</sup>, AbbVie Deutschland GmbH &amp; Co. KG, Germany) and maintained at 37°C and received 0.1 mg/kg buprenorphine as intraperitoneal injection (Temgesic<sup>®</sup>, Reckitt Benckiser Healthcare Ltd., UK) for analgesia. External carotid artery (ECA) and internal carotid artery (ICA) were dissected and a silicon coated suture (Doccol Corp., Redlands, Ca; USA) was introduced and pushed forward through the ICA until the coated top sealed the source of the middle cerebral artery (MCA). Proper positioning of the suture was verified by laser Doppler flowmetry.[<xref ref-type="bibr" rid="pone.0167329.ref012">12</xref>] Mice then recovered in their specified cage. After 90 minutes of occlusion, mice were re-anesthetized for suture withdrawal to allow reperfusion. For Sham group, surgery protocol ended after dissecting the ICA, thus no suture was inserted. In the acute post-operative phase (6 hours after surgery), animals were monitored hourly and every 6–8 hours subsequently. If signs of pain increased during this time, animals were eligible for additional analgesia of 0.1 mg/kg buprenorphine given intraperitoneally every 6–8 hours. 24 hours after reperfusion, animals were deeply anesthetized with isoflurane and euthanized by decapitation. In total, 146 mice underwent surgery, of which 28 died during the induction of the stroke and 7 during the recovery phase. No evidence of adverse effects was identified. The 35 animals who died during surgery or recovery phase were evenly distributed between the groups. Experiments have been repeated accordingly.</p>
</sec>
<sec id="sec004">
<title>Treatments</title>
<p>First experiments were carried out to prove potential neuroprotective effects of OGV related to its content of long-chain omega-3 fatty acids. A control medium-chain lipid emulsion Lipofundin MCT 10%<sup>®</sup> (LPF, B Braun, Germany) and d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS<sup>®</sup>, Sigma-Aldrich, Germany) were tested against saline and OGV in corresponding doses. LPF is also an approved lipid emulsion for parenteral nutrition but lacks long-chain omega-3 fatty acids whereas TPGS is a water-soluble derivative of α-tocopherol. A comparison of the average main ingredients of the two lipid emulsions OGV and LPF is summarized in <xref ref-type="table" rid="pone.0167329.t001">Table 1</xref>.</p>
<table-wrap id="pone.0167329.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0167329.t001</object-id>
<label>Table 1</label> <caption><title>Comparison of average main-ingredients of Omegaven 10% and Lipofundin 10% MCT.</title></caption>
<alternatives>
<graphic id="pone.0167329.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0167329.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="right" style="background-color:#FFFFFF">per 100 mL</th>
<th align="justify" style="background-color:#FFFFFF">Omegaven 10%</th>
<th align="justify" style="background-color:#FFFFFF">Lipofundin 10% MCT</th>
</tr>
</thead>
<tbody>
<tr>
<td align="right" style="background-color:#FFFFFF">Fishoil</td>
<td align="center" style="background-color:#FFFFFF">10,00g</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="right" style="background-color:#FFFFFF">Soybean oil</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">5,00</td>
</tr>
<tr>
<td align="right" style="background-color:#FFFFFF">Medium-chain-triglycerides (MCT)</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">5,00</td>
</tr>
<tr>
<td align="right" style="background-color:#FFFFFF">Glycerol</td>
<td align="center" style="background-color:#FFFFFF">2,50g</td>
<td align="center" style="background-color:#FFFFFF">2,50g</td>
</tr>
<tr>
<td align="right" style="background-color:#FFFFFF">α-Tocopherol</td>
<td align="center" style="background-color:#FFFFFF">0,02g</td>
<td align="center" style="background-color:#FFFFFF">0,01g</td>
</tr>
<tr>
<td align="right" style="background-color:#FFFFFF">(3-sn-Phosphatidyl-)choline from egg</td>
<td align="center" style="background-color:#FFFFFF">1,20g</td>
<td align="center" style="background-color:#FFFFFF">0,8g</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>Throughout the experiments, OGV from a single batch was used to assure constant and comparable concentrations of its ingredients. Subsequently, mice were randomly divided and tested in two subprojects: In subproject 1 treatment took place 5 minutes after completion of the surgical procedures of transient MCAO (a.s., at stroke). In subproject 2 treatment took place after 90 minutes of transient MCAO (a.r., at reperfusion). Each subproject consisted of three groups: (1) Sham, (2) stroke control and (3) stroke OGV. Control and verum groups received a single bolus injection of approximately 150 μL (5 ml/kg b.w.) saline or OGV into the tail vein. According to earlier studies on long-chain omega-3 fatty acids and to exclude possible aggravating effects of other fatty acids such as n-6 fatty acids or saturated fatty acids, we chose saline as a control throughout the experiments.[<xref ref-type="bibr" rid="pone.0167329.ref009">9</xref>–<xref ref-type="bibr" rid="pone.0167329.ref011">11</xref>,<xref ref-type="bibr" rid="pone.0167329.ref013">13</xref>–<xref ref-type="bibr" rid="pone.0167329.ref016">16</xref>]</p>
</sec>
<sec id="sec005">
<title>Neurobehavioral Assessment</title>
<p>Behavioral tests were performed 1 hour before stroke surgery and 24 hours after reperfusion. Neurological impact was scored using a neurological severity score (NSS) adapted from published scores.[<xref ref-type="bibr" rid="pone.0167329.ref017">17</xref>,<xref ref-type="bibr" rid="pone.0167329.ref018">18</xref>] The NSS combines different measures of innate reflex, alertness, physiological behavior and motor ability to score neurological behavior. Neurological performance was scored on a scale of 0 to 16 (most healthy score = 0, most severe score = 16; refer to <xref ref-type="supplementary-material" rid="pone.0167329.s006">S1 Table</xref>).</p>
</sec>
<sec id="sec006">
<title>Infarct area and infarct severity</title>
<p>Infarct area was measured 24 hours after reperfusion. Brain slices were stained with a solution of 1% 2,3,5-triphenyl-tetrazolium chloride (TTC, Sigma-Aldrich, Germany) in phosphate buffered saline (PBS). Striatal brain slices from core region of ischemic stroke (due to MCAO) were used to determine the infarct areas and infarct severity as measured by differences in grayscales. Infarct volumes were determined by whole brain slices.</p>
<p>Stroke severity or amount of living tissue was determined by a grayscale analysis of TTC stained brain slices. The coloring agent allows to differentiate between metabolic active and inactive tissue in a continuous way, as density and intensity which is measured by grayscale varies depending on severity of stroke.[<xref ref-type="bibr" rid="pone.0167329.ref019">19</xref>] The colorless compound is transformed to a red dye by metabolic active tissue whilst metabolic inactive tissue remains white. The difference between the mean grayscale of impacted and healthy contralateral brain hemisphere was calculated for each animal. The lower the value, the more healthy tissue in the analyzed area, as a value of zero implies that there is no difference in the TTC stained color of impacted and contralateral brain hemisphere. Stroke area and grayscale analysis were achieved by Image J software (National Institutes of Health, USA. Version 1.46r).[<xref ref-type="bibr" rid="pone.0167329.ref020">20</xref>]</p>
</sec>
<sec id="sec007">
<title>Preparation of dissociated brain cells (DBC) for <italic>ex vivo</italic> studies</title>
<p>DBC were prepared according to a previously published method using separated hemispheres of brains.[<xref ref-type="bibr" rid="pone.0167329.ref021">21</xref>] Briefly, brain was washed and homogenized in a buffered medium, chopped and pressed through a nylon mesh for separation followed by several centrifugation steps. Subsequently on receipt of the pellet, DBCs were diluted in Dulbecco’s Modified Eagle Medium (DMEM) and seeded into 24 well plates or 96 well plates. Cells were cultured at 37°C under 5% CO<sub>2</sub>. DBCs were used for analysis of MMP and ATP levels 24 hours after reperfusion.</p>
</sec>
<sec id="sec008">
<title>Mitochondrial function</title>
<p><italic>For Mitochondrial isolation</italic>, separated hemispheres of brains were homogenized as previously decribed.[<xref ref-type="bibr" rid="pone.0167329.ref022">22</xref>] Briefly, the sample passes through different centrifugal steps after homogenization to isolate mitochondria which were finally injected into a respirometer (Oxygraph-2k, Oroboros, Innsbruck, Austria).</p>
<p><italic>Mitochondrial respiratory function</italic> was assessed by measuring consumption of oxygen in an Oxygraph-2k respirometer. Titrations of substrates and inhibitors induced different respiratory states. Mitochondrial respiration was normalized to protein content and citrate synthase (CS) activity., respectively. CS activity and protein content were assessed in isolated mitochondria.</p>
<p><italic>Mitochondrial Membrane Potential</italic> (MMP) measurement was assessed in DBCs using the fluorescence colorant rhodamine-123 (R123) for analysis. DBCs were incubated for 15 min (37°C, 5% CO<sub>2</sub>) with 0.4 μM R123. DBC were centrifuged (3000 rpm, 5 min) and washed with HBSS buffer (supplemented with Mg<sup>2+</sup>, Ca<sup>2+</sup>, and HEPES; pH 7.4; 37°C). After adding fresh HBSS to the DBCs, MMP was obtained by measuring the fluorescence of the colorant at an excitation wavelength of 490 nm and at an emission wavelength of 535 nm on a Victor X3 2030 multilabel counter (Perkin Elmer, Rodgau-Jügesheim, Germany). The fluorescence was recorded in four sequential runs and normalized to corresponding protein concentrations.</p>
<p><italic>ATP levels</italic> were determined in DBCs using a ViaLight<sup>®</sup> Plus bioluminescence kit (Lonza, Walkersville, USA). Briefly, DBCs were incubated with lysis reagent followed by incubation with monitoring reagent for additional 5 min. Bioluminescence (linearly associated to ATP concentration) was obtained by a luminescence reader (Victor X3 2030 multilabel counter, Perkin Elmer, Rodgau-Jügesheim, Germany). Concentrations were recorded in two sequential runs and normalized to corresponding protein concentrations.</p>
</sec>
<sec id="sec009">
<title>Microdialysis</title>
<p>Microdialysis was performed as previously described.[<xref ref-type="bibr" rid="pone.0167329.ref023">23</xref>] Briefly, self-made dialysis probe was implanted into mouse striatum one day prior to MCAO. Anesthesia was induced by 2.4% isoflurane with synthetic air and fixed in a stereotaxic framework. The probe (exchange length 2.5mm) was implanted AP +0.5mm; L +2.2mm; DV -3.8mm from bregma and fixed at this position with dental cement (Ivoclar Vivadent AG, Schaan, Liechtenstein). Mice recovered from surgery in their specified cages for 24 hours. Microdialysis was initiated 30min before MCAO and continued until 30min after reperfusion. Fractions were collected separately (before, during and after occlusion). Perfusion liquid was artificial cerebrospinal fluid (aCSF: 147 mmol/LNaCl; 4 mmol/LKCl; 1.2 mmol/L CaCl<sub>2</sub> and 1.2 mmol/L MgCl<sub>2</sub>), the perfusion rate was 2 μL/min. After completion of the microdialysis, animals were sacrificed by decapitation. Metabolites were determined using a CMA-600 microanalyzer (CMA Microdialysis, Stockholm, Sweden).</p>
</sec>
<sec id="sec010">
<title>Protein quantification and Western blot analysis</title>
<p>Protein levels were determined by using Pierce BCA Protein Assay Kit (Thermo Scientific, USA). Brain homogenate of separated hemispheres was used for Western blot experiments. Samples were incubated with primary antibodies [(Cox-2 (sc-1745), Santa Cruz Biotechnology, USA; IL-6 (PP012P2), IL10 (PP007P2), Acris Antibodies, USA] and corresponding secondary antibodies (#401515, #401353 and #401253, Calbiochem, Germany) conjugated to horseradish peroxidase and visualized by ECLplus<sup>TM</sup> Reagent (Amersham Biosciences, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) detected with antibody (MAB374, Chemicon, Germany) and Tubulin detected with antibody (ab6160, Abcam, GB) served as loading control. Band detection and evaluation was achieved with BioRad’s Quantity One software.</p>
</sec>
<sec id="sec011">
<title>Statistics</title>
<p>All data are presented as means ± SEM. Statistical analysis was performed by applying t-test and Mann-Whitney test for groups of two and One-Way ANOVA with Tukey post test for groups of more than three (Prism 5.03, GraphPad Software, USA). A <italic>P</italic> value of &lt; 0.05 was considered statistically significant. If not declared differently, significances always refer to control values.</p>
</sec>
</sec>
<sec id="sec012" sec-type="results">
<title>Results</title>
<sec id="sec013">
<title>Neuroprotection by intravenous infusion of OGV at reperfusion</title>
<p>Transient MCAO for 90 minutes disrupted blood flow and caused ischemia in striatal and cortical areas of the brain as detected by laser Doppler (data not shown) and striatal glucose levels. LPF and TPGS, control items both lacking long-chain omega-3 fatty acids (refer to <xref ref-type="table" rid="pone.0167329.t001">Table 1</xref> for a list of main ingredients) neither affect stroke area (<xref ref-type="fig" rid="pone.0167329.g001">Fig 1A and 1C</xref>) nor stroke severity as measured by grayscale analysis (<xref ref-type="fig" rid="pone.0167329.g001">Fig 1B and 1C</xref>). OGV injection at reperfusion (a.r.) reduced the infarcted area by 21% and severity of stroke by 50% (<xref ref-type="fig" rid="pone.0167329.g001">Fig 1A, 1B and 1C</xref>).</p>
<fig id="pone.0167329.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0167329.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Effects of OGV and control emulsions when applied at reperfusion.</title>
<p>Saline, Lipofundin® (LPF) and d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) in doses equal to OGV when injected at reperfusion (a.r.). (A) Infarct areas and (B) differences in grayscale for LPF, TPGS, and Omegaven 10% (OGV) vs. Saline; n = 6. Mean ± SEM, p*&lt;0.05; p**&lt;0.01; p***&lt;0.001; One-Way ANOVA with Tukey post-test. (C) Representative striatal brain slices for determination of differences in grayscale for each group. Density of grayscale in a representative area from core of infarction (solid circle) was subtracted from corresponding grayscale of contralateral control area (dashed circle). </p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0167329.g001" xlink:type="simple"/>
</fig>
<p>Compared to the stroke control group, OGV a.r. increased the mitochondrial membrane potential by 20% (MMP; <xref ref-type="fig" rid="pone.0167329.g002">Fig 2A</xref>), and ATP levels by 63% (<xref ref-type="fig" rid="pone.0167329.g002">Fig 2B</xref>) which were significantly reduced in dissociated brain cells 24 hours after reperfusion. Protective effects of OGV on cerebral mitochondrial dysfunction were further investigated in isolated mitochondria.</p>
<fig id="pone.0167329.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0167329.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Marker of mitochondrial function after treatment at reperfusion.</title>
<p>Sham-operated mice. (Control) versus stroke control group that received saline (Stroke) and stroke treatment group that received OGV at reperfusion (a.r.). (A) Mitochondrial membrane potential (MMP)- and (B) Adenosine triphosphate (ATP)-levels as measured 24 hours after reperfusion in dissociated brain cells, n = 8; (C) Respiration [pmol oxygen/(s* mg protein)] of different complexes of the respiratory chain were determined in isolated mitochondria, n = 6; (D) Respiratory control ratio (RCR) that indicates the coupling of mitochondrial respiration chain and citrate synthase activity that represents a quantitative marker for mitochondrial mass, n = 6. Mean ± SEM, p*&lt;0.05; p**&lt;0.01; p***&lt;0.001; One-Way ANOVA with Tukey post-test.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0167329.g002" xlink:type="simple"/>
</fig>
<p>Stroke significantly impaired the activity of OXPHOS and complex IV (cytochrome c oxidase) of the mitochondrial respiration chain (<xref ref-type="fig" rid="pone.0167329.g002">Fig 2C</xref>) and reduced the respiratory control ratio (RCR) and citrate synthase activity (<xref ref-type="fig" rid="pone.0167329.g002">Fig 2D</xref>). OGV improved the RCR by 31% (<xref ref-type="fig" rid="pone.0167329.g002">Fig 2D</xref>), indicating enhanced coupling of the respiratory system.[<xref ref-type="bibr" rid="pone.0167329.ref022">22</xref>,<xref ref-type="bibr" rid="pone.0167329.ref024">24</xref>] OGV also increased citrate synthase activity by 71% after stroke (<xref ref-type="fig" rid="pone.0167329.g002">Fig 2D</xref>), indicating enhanced mitochondrial mass.[<xref ref-type="bibr" rid="pone.0167329.ref025">25</xref>]</p>
<p>Although mitochondrial function as well as stroke area and severity of stroke were improved, OGV treatment at reperfusion resulted only in marginally improved neurological severity scores as early as 24 hours after reperfusion (data not shown).</p>
</sec>
<sec id="sec014">
<title>Superior effects of an acute OGV administration</title>
<p>Severe behavioral limitations (score 10 or 11) were manifest in all animals tested 24 h after 90 minutes of MCAO (<xref ref-type="fig" rid="pone.0167329.g003">Fig 3A</xref>). Significant improvement was observed when OGV was injected immediately after onset of MCAO (a.s.) (<xref ref-type="fig" rid="pone.0167329.g003">Fig 3A</xref>), resulting in a significant improved motor function.</p>
<fig id="pone.0167329.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0167329.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Effects of OGV when given at stroke (a.s.).</title>
<p>(A) Neurobehavioral assessment (refer to <xref ref-type="supplementary-material" rid="pone.0167329.s006">S1 Table</xref>) for sham-operated mice (Control) versus control group that received saline (Stroke) and treatment group that received OGV at stroke (a.s.), (B) Representative brain slices for determination of infarct volume and differences in grayscale. (C) Effect on infarct volume and grayscale levels, n = 8. Mean ± SEM, p*&lt;0.05; p**&lt;0.01; p***&lt;0.001; (A) One-Way ANOVA with Tukey post-test, (C) t-test.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0167329.g003" xlink:type="simple"/>
</fig>
<p>MCAO led to steady necrotic lesions including both cortical and subcortical areas of the impacted, left hemisphere (<xref ref-type="fig" rid="pone.0167329.g003">Fig 3B</xref>). OGV injection a.s. reduced infarct volume by 56% as well as severity of stroke by 60% (<xref ref-type="fig" rid="pone.0167329.g003">Fig 3B and 3C</xref>) and restored mitochondrial function to basal values (<xref ref-type="fig" rid="pone.0167329.g004">Fig 4A and 4B</xref>).</p>
<fig id="pone.0167329.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0167329.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Marker of mitochondrial function after treatment at stroke.</title>
<p>Sham mice (Control) versus stroke control group that received saline (Stroke) and stroke treatment group that received OGV at stroke (a.s.). (A) Mitochondrial membrane potential (MMP)- and (B) Adenosine triphosphate (ATP)-levels as measured in dissociated brain cells 24 hours after reperfusion. Energy metabolite levels in striatal core region of stroke for (C) glucose and (D) glutamate as determined by microdialysis 30 minutes before (PRE), 90 minutes during (Stroke) and 30 minutes after (POST) stroke surgery, n = 8. Mean ± SEM, p*&lt;0.05; p**&lt;0.01;p***&lt;0.001; One-Way ANOVA with Tukey post-test.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0167329.g004" xlink:type="simple"/>
</fig>
<p>Glucose and glutamate levels were determined before (PRE), during (Stroke) and after stroke (POST) in extracellular microdialysates collected in the striatum of the ischemic hemisphere (<xref ref-type="fig" rid="pone.0167329.g004">Fig 4C and 4D</xref>). Glucose levels dropped by 86% during stroke and increased after reperfusion (<xref ref-type="fig" rid="pone.0167329.g004">Fig 4C</xref>). Elevated glutamate levels by 740% of basal values were observed during MCAO (<xref ref-type="fig" rid="pone.0167329.g004">Fig 4D</xref>). OGV suppressed the release of glutamate during stroke (<xref ref-type="fig" rid="pone.0167329.g004">Fig 4D</xref>) and enhanced glucose levels in the impacted area (<xref ref-type="fig" rid="pone.0167329.g004">Fig 4C</xref>). Although, the OGV-induced rise in glucose levels was statistically not significant, the data indicate an improved blood supply into the affected tissue.</p>
<p>MCAO significantly increased pro-inflammatory protein levels of cyclooxygenase 2 (COX-2, <xref ref-type="fig" rid="pone.0167329.g005">Fig 5A</xref>) by 540% and interleukin-6 (IL-6 <xref ref-type="fig" rid="pone.0167329.g005">Fig 5B</xref>) by 220% as well as the anti-inflammatory marker Interleukin-10 (IL-10, <xref ref-type="fig" rid="pone.0167329.g005">Fig 5C</xref>) by 160%.</p>
<fig id="pone.0167329.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0167329.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Western Blot analysis of brain homogenates.</title>
<p>Sham-operated mice (Control) versus control group that received saline (Stroke) and treatment group that received OGV at stroke (a.s.). (A) COX-2-, (B) IL-6-, and (C) IL-10 protein levels, n = 8. Mean ± SEM, p*&lt;0.05; p**&lt;0.01; p***&lt;0.001; One-Way ANOVA with Tukey post-test.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0167329.g005" xlink:type="simple"/>
</fig>
<p>Compared to stroke, OGV a.s. significantly reduced the pro-inflammatory marker IL-6 by 49% (<xref ref-type="fig" rid="pone.0167329.g005">Fig 5B</xref>), but had no influence on IL-10 levels. All protein levels were measured 24h post-stroke.</p>
</sec>
</sec>
<sec id="sec015" sec-type="conclusions">
<title>Discussion</title>
<p>The demand for long-chain omega-3 fatty acids escalates dramatically after ischemic stroke to limit the cellular damage by restoring destroyed neuronal membranes. During ischemia, polyunsaturated species from phospholipids (especially arachidonic acid and DHA) undergo significant hydrolysis which was not inversed through reperfusion.[<xref ref-type="bibr" rid="pone.0167329.ref026">26</xref>] We confirmed recent data demonstrating neuroprotective effects of DHA in experimental stroke models when applied at reperfusion.[<xref ref-type="bibr" rid="pone.0167329.ref005">5</xref>,<xref ref-type="bibr" rid="pone.0167329.ref011">11</xref>] Moreover, we report the novel finding that OGV injections shortly after onset of stroke provided superior neuroprotective actions (compared to treatment at reperfusion) on stroke volume, tissue health (as measured by grayscale analysis), mitochondrial function and development of inflammation in a murine MCAO model, emphasizing the importance of an earliest intervention to improve the outcome. OGV is an approved fish oil emulsion for parenteral nutrition containing long-chain omega-3 fatty acids (DHA 18 mg/ml; EPA 21 mg/,ml) and α-tocopherol (0.2 mg/ml). Thus, findings might be translated into a clinical setting. The dosing rationale for this study was based on recommendations of the GV-SOLAS (Gesellschaft für Versuchstierkunde–Society for Laboratory Animal Science) regarding the maximum feasible volume for intravenous substance application in the mouse, which is 5 ml/kg and is equal to our bolus injection of 150 μL in a mouse of approximately 30g weight.[<xref ref-type="bibr" rid="pone.0167329.ref027">27</xref>] This dose is 5 times below the accepted range of OGV in human. Belayev et al. reported toxic effects of 70 mg/kg DHA in rats. Doses of 3.5, 7, 14 and 35 mg/kg DHA showed equal beneficial effects.[<xref ref-type="bibr" rid="pone.0167329.ref011">11</xref>] Taking into account the conversion factor for doses from rats to mice, 3.5, 7, 14, 35 and 70 mg/kg in rats as reported by Belayev et al. correspond to doses of 7, 14, 28, 70 and 140 mg/kg in mice.[<xref ref-type="bibr" rid="pone.0167329.ref028">28</xref>] The bolus injection used in this pilot study contained 90 mg/kg DHA, which is below the dose that showed detrimental effects and within the beneficial dose that was reported by Belayev et al., thus reflecting a maximum non-toxic dose. This study was designed as a pilot study and should test a potentially translational treatment with long-chain omega-3 fatty acid emulsion approved for parenteral nutrition in humans. We identified two time points when treatment could take place in the best case: First, after induction of stroke but before diagnosis, and second, after diagnosis of stroke and lysis/removal of the thrombus. These points reflect the two earliest time points when treatment with OGV would be feasible and could potentially exert maximum effects. As patients with suspected or diagnosed ischemic stroke would receive a central venous access, we chose an intravenous injection as acute way of treatment. As stated above, we carefully chose one dose that should represent a maximum non-toxic dose based on earlier findings in the literature.[<xref ref-type="bibr" rid="pone.0167329.ref011">11</xref>] Beneficial effects of OGV can largely be assigned to their content of long-chain omega-3 fatty acids since experiments using comparable emulsions containing soy oil and medium-chain triglycerides (100 mg/ml) and α-tocopherol (0.2 mg/ml) (LPF or TPGS) in equivalent concentration showed no effects on stroke outcome. Beside DHA, OGV also contains the long-chain omega-3 fatty acid eicosapentaenoic acid (EPA) which also provides beneficial effects.[<xref ref-type="bibr" rid="pone.0167329.ref029">29</xref>] EPA also exerts anti-inflammatory as well as mild vasodilatory effects.[<xref ref-type="bibr" rid="pone.0167329.ref030">30</xref>,<xref ref-type="bibr" rid="pone.0167329.ref031">31</xref>] Exclusive treatment with EPA was shown to be ineffective in a model of hypoxic-ischemic brain injury, thus its neuroprotective potency seems to be lower than that of DHA which mediated strong neuroprotection in the same model.[<xref ref-type="bibr" rid="pone.0167329.ref006">6</xref>] EPA showed additional effects like vasodilatation and improved membrane fluidity that, in combination with DHA, may potentiate neuroprotective actions.[<xref ref-type="bibr" rid="pone.0167329.ref031">31</xref>] The biological precursor of long-chain omega-3 fatty acids DHA and EPA is the shorter-chain fatty acid alpha-linolenic acid (ALA). In the body, ALA is converted to DHA and EPA, but this conversion is ineffective. For example, conversion from ALA to DHA is only about 0–4%.[<xref ref-type="bibr" rid="pone.0167329.ref032">32</xref>] A recent study showed that acute intravenous injection of ALA was insufficient in improving motor recovery after ischemic stroke in mice, whilst dietary long-term supplementation with ALA was able to exert significant protective effects, emphasizing the importance and possibility of nutritional intervention in order to improve outcome in the critically post-stroke recovery phase.[<xref ref-type="bibr" rid="pone.0167329.ref033">33</xref>] Other studies claim that neuroprotective effects are widely attributed to conversion of ALA to DHA and that ALA seems not to be useful for an acute intervention of ischemic stroke.[<xref ref-type="bibr" rid="pone.0167329.ref034">34</xref>] Respective levels of ALA and EPA in the brain are 200–500 fold lower than of DHA, which might be attributed to a rapid metabolism via beta-oxidation and subsequently underline the brain’s need for DHA.[<xref ref-type="bibr" rid="pone.0167329.ref035">35</xref>] Otherwise, Bourourou et al. revealed that protective effects of ALA treatment are linked to an intrinsic effect rather than bioconversation of ALA to DHA as indicated by unchanged DHA levels of the brain after subchronic ALA injections.[<xref ref-type="bibr" rid="pone.0167329.ref033">33</xref>] As OGV also contains certain amounts of ALA, this might also contribute to the observed protective effects in addition to those mediated by e.g. DHA or EPA.[<xref ref-type="bibr" rid="pone.0167329.ref036">36</xref>] Additional data for ALA supplementation and its protective effects are also given by Blondeau et al. who summarizes that potential benefits of ALA are supported by animal studies as well as epidemiologic studies. He also supports the idea of an intravenous therapy targeting neurological conditions and speculates that this may offer significant benefits for patients suffering ischemic conditions.[<xref ref-type="bibr" rid="pone.0167329.ref037">37</xref>] The proposed intervention with OGV goes well with the supposed approach communicated by Blondeau et al. and supports this idea with first data.</p>
<p>In line with earlier reports, microdialysis showed significantly increased glutamate levels in the striatum of control mice which returned to basal levels at reperfusion.[<xref ref-type="bibr" rid="pone.0167329.ref038">38</xref>] Excessive glutamate release during ischemia leads to excitotoxicity that triggers apoptosis and finally neurodegeneration.[<xref ref-type="bibr" rid="pone.0167329.ref039">39</xref>,<xref ref-type="bibr" rid="pone.0167329.ref040">40</xref>] The excessive glutamate release peaks within minutes after ischemia and then slowly decreases within hours, emphasizing the importance of an early treatment if the glutamate mediated excitotoxicity should be targeted effectively to prevent further neuronal death.[<xref ref-type="bibr" rid="pone.0167329.ref012">12</xref>,<xref ref-type="bibr" rid="pone.0167329.ref023">23</xref>,<xref ref-type="bibr" rid="pone.0167329.ref041">41</xref>] We recently showed that the inhibition of the excessive release of glutamate triggered by ischemia results in a reduction of infarct area and enhances motor function.[<xref ref-type="bibr" rid="pone.0167329.ref020">20</xref>] Similarly, OGV treatment shortly after induction of MCAO abolished the release of extracellular glutamate levels and reduced the infarct area which might help to explain why only an acute treatment improved neurological outcome. Presumably, due to the fact that also treatment at reperfusion preserved significant amounts of viable brain tissue, long-term rehabilitation is expected to be better. Supplementation with fish oil was recently shown to be related to reduced cellular damage and enhanced cellular proliferation 6 weeks after ischemic stroke in the rat.[<xref ref-type="bibr" rid="pone.0167329.ref042">42</xref>] OGV numerically enhanced glucose levels. OGV enhances erythrocyte membrane fluidity and thus potently modulates endothelial cell integrity and exert vasodilatory effects which might explain an improved blood supply into the affected tissue, thus leading to slightly improved glucose levels obtained during microdialysis at stroke.[<xref ref-type="bibr" rid="pone.0167329.ref030">30</xref>,<xref ref-type="bibr" rid="pone.0167329.ref031">31</xref>,<xref ref-type="bibr" rid="pone.0167329.ref043">43</xref>] As a consequence, this mechanism might evoke concern about influences on bleeding times. Wachira et al. investigated the influence of (highly concentrated) long-chain omega-3 fatty acids on hemostasis and concluded that bleeding times did not exceed normal limits nor did produce clinically significant bleeding episodes and are rendered safe in monotherapy as well as combination therapy settings, although DHA and EPA exert a mild inhibition of platelet function that was often under detection limits. No support for discontinuing long-chain omega-3 fatty acid supplementation before invasive procedures was found. In contrast, their use improved clinical outcomes in several settings or reduced the risk of bleeding.[<xref ref-type="bibr" rid="pone.0167329.ref030">30</xref>] This finding is supported by a meta-analysis of clinical studies regarding relation of intake of long-chain omega-3 fatty acids and stroke by Larsson et al. who showed that no higher risks nor occurrences of hemorrhagic stroke could be stated, but a statistically significant reduction in stroke risk in relation to long-chain omega-3 fatty acid intake could be found for ischemic stroke that was only significant for ischemic but not hemorrhagic stroke. Larsson et al. attributed this statistical difference to the higher patient counts for ischemic stroke, resulting in higher statistical power.[<xref ref-type="bibr" rid="pone.0167329.ref044">44</xref>] A recent study focused on the concern of hemorrhagic transformation and tested whether DHA increases or decreases the risk of hemorrhagic transformation as a feared complication of cerebral ischemic infarction.[<xref ref-type="bibr" rid="pone.0167329.ref045">45</xref>] The results of this study showed that DHA attenuated hemorrhagic transformation and preserved integrity of the blood-brain-barrier whilst reducing inflammation.</p>
<p>Mitochondrial dysfunction is a major consequence of stroke that impacts brain tissue and causes elevated levels of reactive oxygen species (ROS) in the affected tissue.[<xref ref-type="bibr" rid="pone.0167329.ref046">46</xref>] Ischemia provokes negative alterations in mitochondrial respiration in animal models.[<xref ref-type="bibr" rid="pone.0167329.ref003">3</xref>] In mitochondria, efficacy of cellular respiration was significantly decreased. In contrast, the degree of lipid peroxidation mediated through increased formation of free radicals was significantly increased during ischemia and reperfusion.[<xref ref-type="bibr" rid="pone.0167329.ref020">20</xref>,<xref ref-type="bibr" rid="pone.0167329.ref026">26</xref>,<xref ref-type="bibr" rid="pone.0167329.ref047">47</xref>] In line with recent findings we report on impaired mitochondrial function after MCAO.[<xref ref-type="bibr" rid="pone.0167329.ref041">41</xref>] Intravenous treatment with OGV compensated for stroke-related decrease of mitochondrial respiration and significantly enhanced OXPHOS and cytochrome C oxidase activity. The OXPHOS system is the final biochemical pathway for the production of ATP. Thus, improved respiration led to an enhanced MMP that represents the propulsive power for ATP formation through F0/F1-ATPase (complex V) activity.[<xref ref-type="bibr" rid="pone.0167329.ref048">48</xref>] Accordingly, OGV significantly improved MMP and ATP levels as measured 24 hours after reperfusion.</p>
<p>Inflammation represents a severe and detrimental consequence of stroke that is characterized by an accumulation of inflammatory mediators.[<xref ref-type="bibr" rid="pone.0167329.ref049">49</xref>] Pro-inflammatory mediators such as COX-2 impair mitochondrial activity by inducing accumulation of distinct amounts of ROS through impairing OXPHOS activity.[<xref ref-type="bibr" rid="pone.0167329.ref050">50</xref>] Pro-inflammatory IL-6 is known to be elevated in the acute phase of stroke and high levels of IL-6 are associated with increased stroke volume and less favorable prognosis.[<xref ref-type="bibr" rid="pone.0167329.ref051">51</xref>] Its opponent IL-10 exerts anti-inflammatory effects, provides neuroprotection in ischemic stroke and reduced infarct volume at raised levels.[<xref ref-type="bibr" rid="pone.0167329.ref052">52</xref>] Levels of IL-6 (as part of the pro-inflammatory answer) and IL-10 (as part of the physiological repair mechanism to control the inflammatory answer) were significantly increased after transient MCAO which may involve inhibition of nuclear factor κB activation and an ERK mediated pro-survival cascade.[<xref ref-type="bibr" rid="pone.0167329.ref053">53</xref>] Several studies reported that treatment with anti-inflammatory drugs reduced infarct size and brain edema.[<xref ref-type="bibr" rid="pone.0167329.ref054">54</xref>] Long-chain omega-3 fatty acids are considered to be suppressors of neuroinflammation with several mechanisms of action.[<xref ref-type="bibr" rid="pone.0167329.ref035">35</xref>] Long-chain omega-3 fatty acids are actively biosynthesized to specialized pro-resolving mediators (SPM), a family of neuroprotective mediators that are involved in the resolution of inflammation.[<xref ref-type="bibr" rid="pone.0167329.ref055">55</xref>] This family is comprised of lipoxins, resolvins, protectins and maresins. Classic lipid mediators are formed from arachidonic acid and can exert pro-inflammatory (leukotrienes) or anti-inflammatory (lipoxins) actions. EPA can be biosynthesized to a class of resolvins (e-series resolvins) and DHA to several classes of resolvins (d-series resolvins), protectins and maresins which are all actively involved in the resolution of inflammation.[<xref ref-type="bibr" rid="pone.0167329.ref030">30</xref>,<xref ref-type="bibr" rid="pone.0167329.ref055">55</xref>–<xref ref-type="bibr" rid="pone.0167329.ref057">57</xref>] Resolution of inflammation by SPMs involves several mechanisms like neutrophil recruitment, stimulation of clearance mediated by macrophages, counterregulation of pro-inflammatory mediators such as COX-2 or IL-6 and tissue remodeling.[<xref ref-type="bibr" rid="pone.0167329.ref056">56</xref>] Neuroprotectin D1 (NPD-1) represents one of the first and most prominent neuroprotective metabolites of DHA which was identified by Bazan et al. earlier.[<xref ref-type="bibr" rid="pone.0167329.ref058">58</xref>,<xref ref-type="bibr" rid="pone.0167329.ref059">59</xref>] NPD-1 is a protectin that attenuates leukocyte infiltration, inhibits pro-inflammatory signaling and reduces infarct size in animal models of ischemic stroke via inhibition of Nf-κB pathway activation, increased expression of anti-apoptotic proteins like Bcl-2 and decreased expression of pro-apoptotic protein such as Bax.[<xref ref-type="bibr" rid="pone.0167329.ref005">5</xref>,<xref ref-type="bibr" rid="pone.0167329.ref060">60</xref>,<xref ref-type="bibr" rid="pone.0167329.ref061">61</xref>] Since DHA can be converted to several different classes of SPMs which each of them individually exert potent neuroprotective and anti-inflammatory effects, it is one of the most important members of long-chain omega-3 fatty acids.[<xref ref-type="bibr" rid="pone.0167329.ref056">56</xref>] OGV treatment significantly decreased protein levels of IL-6 confirming its anti-inflammatory properties.[<xref ref-type="bibr" rid="pone.0167329.ref062">62</xref>] Our experiments indicate that transient MCAO induced inflammatory and anti-inflammatory proteins and that OGV diminished the pro-inflammatory response only. A crucial point in time for inflammation is the moment of reperfusion. Paradoxically, reperfusion after removal of the thrombus does not improve the overall situation of the brain. As mitochondria experience dysfunction due to previously restricted supply with blood, glucose and oxygen, complexes of the respiratory chain do not work as intended: Components of the oxidative phosphorylation (OxPhos) are phosphorylized under physiological conditions and stabilize mitochondrial membrane potential in a range between 80–140 mV what is advantageous for the production of energy.[<xref ref-type="bibr" rid="pone.0167329.ref063">63</xref>] Following ischemia, several enzymes get activated that mediates dephosphorylation of components of the OxPhos which triggers a hyperactive state with a membrane potential above 150 mV. This hyperactivation does not result in consequences during ischemia due to the lack of oxygen. But after reperfusion, hyperactivated OxPhos components are supplied with oxygen, resulting in exponentially increased production of reactive oxygen species triggering further inflammation and apoptosis.[<xref ref-type="bibr" rid="pone.0167329.ref063">63</xref>] This detrimental phenomenon is called reperfusion-injury, emphasizing the need of an early intervention.[<xref ref-type="bibr" rid="pone.0167329.ref064">64</xref>]</p>
<p>Our data identified intravenous injection of OGV shortly after onset of transient MCAO as possible early medical management which could play a crucial role in inhibiting further brain damage mediated by ischemic stroke.[<xref ref-type="bibr" rid="pone.0167329.ref065">65</xref>] As literature did not reveal any concerns about possible influences of long-chain omega-3 fatty acids on bleeding times, treatment could also be started precautionary when stroke diagnosis is not fully performed yet. [<xref ref-type="bibr" rid="pone.0167329.ref030">30</xref>,<xref ref-type="bibr" rid="pone.0167329.ref044">44</xref>] Earliest neuroprotective treatment of ischemic stroke even before removal of thrombus showed best effects in our pilot study and was able to improve functional short-term outcome. This may be related to the reperfusion-injury that could be targeted by anti-inflammatory and anti-apoptotic long-chain omega-3 fatty acids and their neuroprotective metabolites when given during onset of ischemia. Although this pilot study showed short term effects only, it proved effectiveness of the proposed treatment. Further studies are needed to investigate the long-term effects of the proposed treatment and possibly further dosing regimens. Nevertheless, our results provide a translational approach that might contribute to a new and acute treatment of ischemic stroke in the clinics.</p>
</sec>
<sec id="sec016" sec-type="conclusions">
<title>Conclusion</title>
<p>In summary, treatment provided distinct neuroprotective properties in acute focal cerebral ischemia in mice by attenuating mitochondrial dysfunction as well as neuroinflammation and excitotoxicity. Neuroprotective effects were associated with the long-chain omega-3 fatty acid content of the lipid emulsion. Thus, intravenous administration of OGV might be an early and safe option for interventions even before diagnosis of ischemic stroke has been established. The results of this study might provide first translational data for an early clinical management of ischemic stroke with OGV which is pivotal to prevent further brain damage.</p>
</sec>
<sec id="sec017">
<title>Supporting Information</title>
<supplementary-material id="pone.0167329.s001" position="float" xlink:href="info:doi/10.1371/journal.pone.0167329.s001" xlink:type="simple">
<label>S1 Dataset</label>
<caption>
<title>Raw data of <xref ref-type="fig" rid="pone.0167329.g001">Fig 1</xref>.</title>
<p>(PZF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0167329.s002" position="float" xlink:href="info:doi/10.1371/journal.pone.0167329.s002" xlink:type="simple">
<label>S2 Dataset</label>
<caption>
<title>Raw data of <xref ref-type="fig" rid="pone.0167329.g002">Fig 2</xref>.</title>
<p>(PZF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0167329.s003" position="float" xlink:href="info:doi/10.1371/journal.pone.0167329.s003" xlink:type="simple">
<label>S3 Dataset</label>
<caption>
<title>Raw data of <xref ref-type="fig" rid="pone.0167329.g003">Fig 3</xref>.</title>
<p>(PZF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0167329.s004" position="float" xlink:href="info:doi/10.1371/journal.pone.0167329.s004" xlink:type="simple">
<label>S4 Dataset</label>
<caption>
<title>Raw data of <xref ref-type="fig" rid="pone.0167329.g004">Fig 4</xref>.</title>
<p>(PZF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0167329.s005" position="float" xlink:href="info:doi/10.1371/journal.pone.0167329.s005" xlink:type="simple">
<label>S5 Dataset</label>
<caption>
<title>Raw data of <xref ref-type="fig" rid="pone.0167329.g005">Fig 5</xref>.</title>
<p>(PZF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0167329.s006" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0167329.s006" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>List of tasks and scoring for the Neurological Severity Score (NSS).</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0167329.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jauch</surname> <given-names>EC</given-names></name>, <name name-style="western"><surname>Saver</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Adams</surname> <given-names>HP</given-names></name>, <name name-style="western"><surname>Bruno</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Connors</surname> <given-names>JJB</given-names></name>, <name name-style="western"><surname>Demaerschalk</surname> <given-names>BM</given-names></name>, <etal>et al</etal>. <article-title>Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association</article-title>. <source>Stroke</source>. <year>2013</year>;<volume>44</volume>(<issue>3</issue>):<fpage>870</fpage>–<lpage>947</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STR.0b013e318284056a" xlink:type="simple">10.1161/STR.0b013e318284056a</ext-link></comment> <object-id pub-id-type="pmid">23370205</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Woodruff</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Thundyil</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Tang</surname> <given-names>S-C</given-names></name>, <name name-style="western"><surname>Sobey</surname> <given-names>CG</given-names></name>, <name name-style="western"><surname>Taylor</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Arumugam T</surname> <given-names>V</given-names></name>. <article-title>Pathophysiology, treatment, and animal and cellular models of human ischemic stroke</article-title>. <source>Mol Neurodegener</source>. <year>2011</year> <month>Jan</month>;<volume>6</volume>(<issue>1</issue>):<fpage>11</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1750-1326-6-11" xlink:type="simple">10.1186/1750-1326-6-11</ext-link></comment> <object-id pub-id-type="pmid">21266064</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Niizuma</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Endo</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>PH</given-names></name>. <article-title>Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival</article-title>. <source>J Neurochem</source>. <year>2010</year>;<volume>109</volume>(<issue>Suppl 1</issue>):<fpage>133</fpage>–<lpage>8</lpage>.</mixed-citation></ref>
<ref id="pone.0167329.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vosler</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>Graham</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Wechsler</surname> <given-names>LR</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>J</given-names></name>. <article-title>Mitochondrial targets for stroke: focusing basic science research toward development of clinically translatable therapeutics</article-title>. <source>Stroke</source>. <year>2009</year>;<volume>40</volume>(<issue>9</issue>):<fpage>3149</fpage>–<lpage>55</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.108.543769" xlink:type="simple">10.1161/STROKEAHA.108.543769</ext-link></comment> <object-id pub-id-type="pmid">19478227</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Belayev</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Khoutorova</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Atkins</surname> <given-names>KD</given-names></name>, <name name-style="western"><surname>Eady</surname> <given-names>TN</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Docosahexaenoic Acid Therapy of Experimental Ischemic Stroke</article-title>. <source>Transl Stroke Res</source>. <year>2011</year> <month>Mar</month>;<volume>2</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>41</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12975-010-0046-0" xlink:type="simple">10.1007/s12975-010-0046-0</ext-link></comment> <object-id pub-id-type="pmid">21423332</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Williams</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Mayurasakorn</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Vannucci</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Mastropietro</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Bazan</surname> <given-names>NG</given-names></name>, <name name-style="western"><surname>Ten</surname> <given-names>VS</given-names></name>, <etal>et al</etal>. <article-title>N-3 fatty acid rich triglyceride emulsions are neuroprotective after cerebral hypoxic-ischemic injury in neonatal mice</article-title>. <source>PLoS One</source>. Public Library of Science; <year>2013</year> <month>Jan</month> <day>20</day>;<volume>8</volume>(<issue>2</issue>):<fpage>e56233</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0056233" xlink:type="simple">10.1371/journal.pone.0056233</ext-link></comment> <object-id pub-id-type="pmid">23437099</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maldonado</surname> <given-names>NJ</given-names></name>, <name name-style="western"><surname>Kazmi</surname> <given-names>SO</given-names></name>, <name name-style="western"><surname>Suarez</surname> <given-names>JI</given-names></name>. <article-title>Update in the management of acute ischemic stroke</article-title>. <source>Crit Care Clin</source>. <year>2014</year> <month>Oct</month>;<volume>30</volume>(<issue>4</issue>):<fpage>673</fpage>–<lpage>97</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ccc.2014.06.002" xlink:type="simple">10.1016/j.ccc.2014.06.002</ext-link></comment> <object-id pub-id-type="pmid">25257735</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Reagan-Shaw</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nihal</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ahmad</surname> <given-names>N</given-names></name>. <article-title>Dose translation from animal to human studies revisited</article-title>. <source>FASEB J</source>. <year>2008</year>;<volume>22</volume>(<issue>3</issue>):<fpage>659</fpage>–<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1096/fj.07-9574LSF" xlink:type="simple">10.1096/fj.07-9574LSF</ext-link></comment> <object-id pub-id-type="pmid">17942826</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eady</surname> <given-names>TN</given-names></name>, <name name-style="western"><surname>Khoutorova</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Anzola</surname> <given-names>D V</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>S-H</given-names></name>, <name name-style="western"><surname>Obenaus</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mohd-Yusof</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Acute treatment with docosahexaenoic acid complexed to albumin reduces injury after a permanent focal cerebral ischemia in rats</article-title>. <source>PLoS One</source>. <year>2013</year> <month>Jan</month>;<volume>8</volume>(<issue>10</issue>):<fpage>e77237</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0077237" xlink:type="simple">10.1371/journal.pone.0077237</ext-link></comment> <object-id pub-id-type="pmid">24194876</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hong</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Belayev</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Khoutorova</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Obenaus</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bazan</surname> <given-names>NG</given-names></name>. <article-title>Docosahexaenoic acid confers enduring neuroprotection in experimental stroke</article-title>. <source>J Neurol Sci</source>. The Authors; <year>2014</year>;<volume>338</volume>(<issue>1–2</issue>):<fpage>135</fpage>–<lpage>41</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jns.2013.12.033" xlink:type="simple">10.1016/j.jns.2013.12.033</ext-link></comment> <object-id pub-id-type="pmid">24433927</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Belayev</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Khoutorova</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Atkins</surname> <given-names>KD</given-names></name>, <name name-style="western"><surname>Bazan</surname> <given-names>NG</given-names></name>. <article-title>Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient, focal cerebral ischemia</article-title>. <source>Stroke</source>. <year>2009</year> <month>Sep</month>;<volume>40</volume>(<issue>9</issue>):<fpage>3121</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.109.555979" xlink:type="simple">10.1161/STROKEAHA.109.555979</ext-link></comment> <object-id pub-id-type="pmid">19542051</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwarzkopf</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Koch</surname> <given-names>K a.</given-names></name>, <name name-style="western"><surname>Klein</surname> <given-names>J</given-names></name>. <article-title>Neurodegeneration after transient brain ischemia in aged mice: Beneficial effects of bilobalide</article-title>. <source>Brain Res</source>. <year>2013</year>;<volume>1529</volume>:<fpage>178</fpage>–<lpage>87</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.brainres.2013.07.003" xlink:type="simple">10.1016/j.brainres.2013.07.003</ext-link></comment> <object-id pub-id-type="pmid">23850645</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Byrne</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>McGuinness</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Hill</surname> <given-names>ADK</given-names></name>, <name name-style="western"><surname>Redmond</surname> <given-names>MJ</given-names></name>. <article-title>Intravenous omega-3, a technique to prevent an excessive innate immune response to cardiac surgery in a rodent gut ischemia model</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2011</year> <month>Mar</month>;<volume>141</volume>(<issue>3</issue>):<fpage>803</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jtcvs.2010.04.030" xlink:type="simple">10.1016/j.jtcvs.2010.04.030</ext-link></comment> <object-id pub-id-type="pmid">20708753</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gercek</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Yildirim</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Konya</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Bozkurt</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ozgen</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kilic</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Effects of parenteral fish-oil emulsion (Omegaven) on cutaneous wound healing in rats treated with dexamethasone</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <month>Jan</month>;<volume>31</volume>(<issue>3</issue>):<fpage>161</fpage>–<lpage>6</lpage>. <object-id pub-id-type="pmid">17463139</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kilian</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Gregor</surname> <given-names>JI</given-names></name>, <name name-style="western"><surname>Heukamp</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Wagner</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Walz</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Schimke</surname> <given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Early inhibition of prostaglandin synthesis by n-3 fatty acids determinates histologic severity of necrotizing pancreatitis</article-title>. <source>Pancreas</source>. <year>2009</year> <month>May</month>;<volume>38</volume>(<issue>4</issue>):<fpage>436</fpage>–<lpage>41</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MPA.0b013e318198283b" xlink:type="simple">10.1097/MPA.0b013e318198283b</ext-link></comment> <object-id pub-id-type="pmid">19295455</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Emon</surname> <given-names>ST</given-names></name>, <name name-style="western"><surname>Irban</surname> <given-names>AG</given-names></name>, <name name-style="western"><surname>Bozkurt</surname> <given-names>SU</given-names></name>, <name name-style="western"><surname>Akakin</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Konya</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Ozgen</surname> <given-names>S</given-names></name>. <article-title>Effects of parenteral nutritional support with fish-oil emulsion on spinal cord recovery in rats with traumatic spinal cord injury</article-title>. <source>Turk Neurosurg</source>. <year>2011</year> <month>Jan</month>;<volume>21</volume>(<issue>2</issue>):<fpage>197</fpage>–<lpage>202</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5137/1019-5149.JTN.3523-10.2" xlink:type="simple">10.5137/1019-5149.JTN.3523-10.2</ext-link></comment> <object-id pub-id-type="pmid">21534202</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Therapeutic Benefit of Intravenous Administration of Bone Marrow Stromal Cells After Cerebral Ischemia in Rats</article-title>. <source>Stroke</source>. <year>2001</year> <month>Apr</month> <day>1</day>;<volume>32</volume>(<issue>4</issue>):<fpage>1005</fpage>–<lpage>11</lpage>. <object-id pub-id-type="pmid">11283404</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stahel</surname> <given-names>PF</given-names></name>, <name name-style="western"><surname>Shohami</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Younis</surname> <given-names>FM</given-names></name>, <name name-style="western"><surname>Kariya</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Otto</surname> <given-names>VI</given-names></name>, <name name-style="western"><surname>Lenzlinger</surname> <given-names>PM</given-names></name>, <etal>et al</etal>. <article-title>Experimental closed head injury: analysis of neurological outcome, blood-brain barrier dysfunction, intracranial neutrophil infiltration, and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2000</year> <month>Mar</month>;<volume>20</volume>(<issue>2</issue>):<fpage>369</fpage>–<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/00004647-200002000-00019" xlink:type="simple">10.1097/00004647-200002000-00019</ext-link></comment> <object-id pub-id-type="pmid">10698075</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Horn</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Klein</surname> <given-names>J</given-names></name>. <article-title>Neuroprotective effects of lactate in brain ischemia: dependence on anesthetic drugs</article-title>. <source>Neurochem Int</source>. <year>2013</year> <month>Feb</month>;<volume>62</volume>(<issue>3</issue>):<fpage>251</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neuint.2012.12.017" xlink:type="simple">10.1016/j.neuint.2012.12.017</ext-link></comment> <object-id pub-id-type="pmid">23298645</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwarzkopf</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Hagl</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Eckert</surname> <given-names>GP</given-names></name>, <name name-style="western"><surname>Klein</surname> <given-names>J</given-names></name>. <article-title>Neuroprotection by bilobalide in ischemia: improvement of mitochondrial function</article-title>. <source>Pharmazie</source>. <year>2013</year> <month>Jul</month>;<volume>68</volume>(<issue>7</issue>):<fpage>584</fpage>–<lpage>9</lpage>. <object-id pub-id-type="pmid">23923641</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Franke</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Nöldner</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Abdel-Kader</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Johnson-Anuna</surname> <given-names>LN</given-names></name>, <name name-style="western"><surname>Gibson Wood</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Müller</surname> <given-names>WE</given-names></name>, <etal>et al</etal>. <article-title>Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment</article-title>. <source>Neurobiol Dis</source>. <year>2007</year> <month>Mar</month>;<volume>25</volume>(<issue>2</issue>):<fpage>438</fpage>–<lpage>45</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.nbd.2006.10.004" xlink:type="simple">10.1016/j.nbd.2006.10.004</ext-link></comment> <object-id pub-id-type="pmid">17157514</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hagl</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kocher</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Schiborr</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Eckert</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Ciobanu</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Birringer</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Rice bran extract protects from mitochondrial dysfunction in guinea pig brains Article</article-title>. <source>Pharmacol Res</source>. Elsevier Ltd; <year>2013</year> <month>Jul</month> <day>1</day>;<volume>76C</volume>:<fpage>17</fpage>–<lpage>27</lpage>.</mixed-citation></ref>
<ref id="pone.0167329.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lang</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Kiewert</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Mdzinarishvili</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Schwarzkopf</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Sumbria</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hartmann</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Neuroprotective effects of bilobalide are accompanied by a reduction of ischemia-induced glutamate release in vivo</article-title>. <source>Brain Res</source>. Elsevier B.V.; <year>2011</year> <month>Nov</month> <day>24</day>;<volume>1425</volume>:<fpage>155</fpage>–<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.brainres.2011.10.005" xlink:type="simple">10.1016/j.brainres.2011.10.005</ext-link></comment> <object-id pub-id-type="pmid">22032877</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>White</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Culmsee</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Beart</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Eckert</surname> <given-names>GP</given-names></name>, <name name-style="western"><surname>Schiborr</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hagl</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Curcumin prevents mitochondrial dysfunction in the brain of the senescence-accelerated mouse-prone 8</article-title>. <source>Neurochem Int</source>. Elsevier Ltd; <year>2013</year> <month>Apr</month>;<volume>62</volume>(<issue>5</issue>):<fpage>595</fpage>–<lpage>602</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neuint.2013.02.014" xlink:type="simple">10.1016/j.neuint.2013.02.014</ext-link></comment> <object-id pub-id-type="pmid">23422877</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Larsen</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nielsen</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hansen</surname> <given-names>CN</given-names></name>, <name name-style="western"><surname>Nielsen</surname> <given-names>LB</given-names></name>, <name name-style="western"><surname>Wibrand</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Stride</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects</article-title>. <source>J Physiol</source>. <year>2012</year> <month>Jul</month> <day>15</day>;<volume>590</volume>(<issue>Pt 14</issue>):<fpage>3349</fpage>–<lpage>60</lpage>.</mixed-citation></ref>
<ref id="pone.0167329.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sun</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Gilboe</surname> <given-names>DD</given-names></name>. <article-title>Ischemia-induced changes in cerebral mitochondrial free fatty acids, phospholipids, and respiration in the rat</article-title>. <source>J Neurochem</source>. <year>1994</year> <month>May</month>;<volume>62</volume>(<issue>5</issue>):<fpage>1921</fpage>–<lpage>8</lpage>. <object-id pub-id-type="pmid">8158140</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref027"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Gesellschaft für Versuchstierkunde (GV-SOLAS), Tierärztliche Vereinigung für Tierschutz. Empfehlung zur Substanzapplikation bei Versuchstieren. GV-SOLAS 2010 p. 4.</mixed-citation></ref>
<ref id="pone.0167329.ref028"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers Pharmacology and Toxicology Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials. FDA Maryland 2005 p. 1–30.</mixed-citation></ref>
<ref id="pone.0167329.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tanaka</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Ishikawa</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Yokoyama</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Origasa</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Matsuzaki</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Saito</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial</article-title>. <source>Stroke</source>. <year>2008</year> <month>Jul</month> <day>1</day>;<volume>39</volume>(<issue>7</issue>):<fpage>2052</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.107.509455" xlink:type="simple">10.1161/STROKEAHA.107.509455</ext-link></comment> <object-id pub-id-type="pmid">18451347</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wachira</surname> <given-names>JK</given-names></name>, <name name-style="western"><surname>Larson</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Harris</surname> <given-names>WS</given-names></name>. <article-title>n-3 Fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights</article-title>. <source>Br J Nutr</source>. <year>2014</year> <month>May</month>;<volume>111</volume>(<issue>9</issue>):<fpage>1652</fpage>–<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1017/S000711451300425X" xlink:type="simple">10.1017/S000711451300425X</ext-link></comment> <object-id pub-id-type="pmid">24472372</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Borow</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Nelson</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Mason</surname> <given-names>RP</given-names></name>. <article-title>Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis</article-title>. <source>Atherosclerosis</source>. Elsevier; <year>2015</year> <month>Sep</month>;<volume>242</volume>(<issue>1</issue>):<fpage>357</fpage>–<lpage>66</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.atherosclerosis.2015.07.035" xlink:type="simple">10.1016/j.atherosclerosis.2015.07.035</ext-link></comment> <object-id pub-id-type="pmid">26253795</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mozaffarian</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>JHY</given-names></name>. <article-title>Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year> <month>Nov</month> <day>8</day>;<volume>58</volume>(<issue>20</issue>):<fpage>2047</fpage>–<lpage>67</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jacc.2011.06.063" xlink:type="simple">10.1016/j.jacc.2011.06.063</ext-link></comment> <object-id pub-id-type="pmid">22051327</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bourourou</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Heurteaux</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Blondeau</surname> <given-names>N</given-names></name>. <article-title>Alpha-linolenic acid given as enteral or parenteral nutritional intervention against sensorimotor and cognitive deficits in a mouse model of ischemic stroke</article-title>. <source>Neuropharmacology</source>. <year>2016</year>;<volume>108</volume>:<fpage>60</fpage>–<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neuropharm.2016.04.040" xlink:type="simple">10.1016/j.neuropharm.2016.04.040</ext-link></comment> <object-id pub-id-type="pmid">27133376</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Calder</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Yaqoob</surname> <given-names>P</given-names></name>. <article-title>Understanding omega-3 polyunsaturated fatty acids</article-title>. <source>Postgrad Med</source>. <year>2009</year> <month>Nov</month>;<volume>121</volume>(<issue>6</issue>):<fpage>148</fpage>–<lpage>57</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3810/pgm.2009.11.2083" xlink:type="simple">10.3810/pgm.2009.11.2083</ext-link></comment> <object-id pub-id-type="pmid">19940425</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Orr</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Trépanier</surname> <given-names>M-O</given-names></name>, <name name-style="western"><surname>Bazinet</surname> <given-names>RP</given-names></name>. <article-title>n-3 Polyunsaturated fatty acids in animal models with neuroinflammation</article-title>. <source>Prostaglandins Leukot Essent Fatty Acids</source>. <year>2013</year> <month>Jan</month>;<volume>88</volume>(<issue>1</issue>):<fpage>97</fpage>–<lpage>103</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.plefa.2012.05.008" xlink:type="simple">10.1016/j.plefa.2012.05.008</ext-link></comment> <object-id pub-id-type="pmid">22770766</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Amusquivar</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Sánchez</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hyde</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Laws</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Clarke</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Herrera</surname> <given-names>E</given-names></name>. <article-title>Influence of Fatty Acid Profile of Total Parenteral Nutrition Emulsions on the Fatty Acid Composition of Different Tissues of Piglets</article-title>. <source>Lipids</source>. Springer-Verlag; <year>2008</year> <month>Aug</month> <day>9</day>;<volume>43</volume>(<issue>8</issue>):<fpage>713</fpage>–<lpage>22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11745-008-3180-7" xlink:type="simple">10.1007/s11745-008-3180-7</ext-link></comment> <object-id pub-id-type="pmid">18491157</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Blondeau</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Lipsky</surname> <given-names>RH</given-names></name>, <name name-style="western"><surname>Bourourou</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Duncan</surname> <given-names>MW</given-names></name>, <name name-style="western"><surname>Gorelick</surname> <given-names>PB</given-names></name>, <name name-style="western"><surname>Marini</surname> <given-names>AM</given-names></name>. <article-title>Alpha-linolenic acid: an omega-3 fatty acid with neuroprotective properties-ready for use in the stroke clinic?</article-title> <source>Biomed Res Int</source>. Hindawi Publishing Corporation; <year>2015</year>;<volume>2015</volume>:<fpage>519830</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2015/519830" xlink:type="simple">10.1155/2015/519830</ext-link></comment> <object-id pub-id-type="pmid">25789320</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kiewert</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Mdzinarishvili</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hartmann</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Bickel</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Klein</surname> <given-names>J</given-names></name>. <article-title>Metabolic and transmitter changes in core and penumbra after middle cerebral artery occlusion in mice</article-title>. <source>Brain Res</source>. Elsevier B.V.; <year>2010</year> <month>Feb</month> <day>2</day>;<volume>1312</volume>:<fpage>101</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.brainres.2009.11.068" xlink:type="simple">10.1016/j.brainres.2009.11.068</ext-link></comment> <object-id pub-id-type="pmid">19961839</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lipton</surname> <given-names>P</given-names></name>. <article-title>Ischemic cell death in brain neurons</article-title>. <source>Physiol Rev</source>. <year>1999</year> <month>Oct</month>;<volume>79</volume>(<issue>4</issue>):<fpage>1431</fpage>–<lpage>568</lpage>. <object-id pub-id-type="pmid">10508238</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Szydlowska</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Tymianski</surname> <given-names>M</given-names></name>. <article-title>Calcium, ischemia and excitotoxicity</article-title>. <source>Cell Calcium</source>. <year>2010</year> <month>Feb</month>;<volume>47</volume>(<issue>2</issue>):<fpage>122</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ceca.2010.01.003" xlink:type="simple">10.1016/j.ceca.2010.01.003</ext-link></comment> <object-id pub-id-type="pmid">20167368</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwarzkopf</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Koch</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Klein</surname> <given-names>J</given-names></name>. <article-title>Reduced severity of ischemic stroke and improvement of mitochondrial function after dietary treatment with the anaplerotic substance triheptanoin</article-title>. <source>Neuroscience</source>. <year>2015</year> <month>Aug</month> <day>6</day>;<volume>300</volume>:<fpage>201</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neuroscience.2015.05.014" xlink:type="simple">10.1016/j.neuroscience.2015.05.014</ext-link></comment> <object-id pub-id-type="pmid">25982559</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pascoe</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Howells</surname> <given-names>DW</given-names></name>, <name name-style="western"><surname>Carey</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Crewther</surname> <given-names>SG</given-names></name>. <article-title>Fish oil supplementation associated with decreased cellular degeneration and increased cellular proliferation 6 weeks after middle cerebral artery occlusion in the rat</article-title>. <source>Neuropsychiatr Dis Treat</source>. <year>2015</year>;<volume>11</volume>:<fpage>153</fpage>–<lpage>64</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2147/NDT.S72925" xlink:type="simple">10.2147/NDT.S72925</ext-link></comment> <object-id pub-id-type="pmid">25609971</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Harvey</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Pavlina</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Zaloga</surname> <given-names>GP</given-names></name>, <name name-style="western"><surname>Siddiqui</surname> <given-names>RA</given-names></name>. <article-title>Modulation of endothelial cell integrity and inflammatory activation by commercial lipid emulsions</article-title>. <source>Lipids Health Dis</source>. <year>2015</year> <month>Jan</month>;<volume>14</volume>:<fpage>9</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s12944-015-0005-6" xlink:type="simple">10.1186/s12944-015-0005-6</ext-link></comment> <object-id pub-id-type="pmid">25888960</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Larsson</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Orsini</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Wolk</surname> <given-names>A</given-names></name>. <article-title>Long-chain omega-3 polyunsaturated fatty acids and risk of stroke: a meta-analysis</article-title>. <source>Eur J Epidemiol</source>. <year>2012</year> <month>Dec</month>;<volume>27</volume>(<issue>12</issue>):<fpage>895</fpage>–<lpage>901</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10654-012-9748-9" xlink:type="simple">10.1007/s10654-012-9748-9</ext-link></comment> <object-id pub-id-type="pmid">23179632</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Wan</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wen</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Zhao</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Docosahexaenoic acid attenuates hyperglycemia-enhanced hemorrhagic transformation after transient focal cerebral ischemia in rats</article-title>. <source>Neuroscience</source>. <year>2015</year>;<volume>301</volume>:<fpage>471</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neuroscience.2015.06.024" xlink:type="simple">10.1016/j.neuroscience.2015.06.024</ext-link></comment> <object-id pub-id-type="pmid">26102005</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eckert</surname> <given-names>GP</given-names></name>, <name name-style="western"><surname>Lipka</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Muller</surname> <given-names>WE</given-names></name>. <article-title>Omega-3 fatty acids in neurodegenerative diseases: focus on mitochondria</article-title>. <source>Prostaglandins Leukot Essent Fatty Acids</source>. Elsevier; <year>2013</year> <month>Jan</month>;<volume>88</volume>(<issue>1</issue>):<fpage>105</fpage>–<lpage>14</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.plefa.2012.05.006" xlink:type="simple">10.1016/j.plefa.2012.05.006</ext-link></comment> <object-id pub-id-type="pmid">22727983</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nakahara</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Kikuchi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Taki</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Nishi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kito</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Yonekawa</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Degradation of mitochondrial phospholipids during experimental cerebral ischemia in rats</article-title>. <source>J Neurochem</source>. <year>1991</year> <month>Sep</month>;<volume>57</volume>(<issue>3</issue>):<fpage>839</fpage>–<lpage>44</lpage>. <object-id pub-id-type="pmid">1650395</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Murphy</surname> <given-names>MP</given-names></name>. <article-title>How mitochondria produce reactive oxygen species</article-title>. <source>Biochem J</source>. <year>2009</year> <month>Jan</month> <day>1</day>;<volume>417</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1042/BJ20081386" xlink:type="simple">10.1042/BJ20081386</ext-link></comment> <object-id pub-id-type="pmid">19061483</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Tang</surname> <given-names>XN</given-names></name>, <name name-style="western"><surname>Yenari</surname> <given-names>MA</given-names></name>. <article-title>The inflammatory response in stroke</article-title>. <source>J Neuroimmunol</source>. <year>2007</year> <month>Mar</month>;<volume>184</volume>(<issue>1–2</issue>):<fpage>53</fpage>–<lpage>68</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jneuroim.2006.11.014" xlink:type="simple">10.1016/j.jneuroim.2006.11.014</ext-link></comment> <object-id pub-id-type="pmid">17188755</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>López-Armada</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Riveiro-Naveira</surname> <given-names>RR</given-names></name>, <name name-style="western"><surname>Vaamonde-García</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Valcárcel-Ares</surname> <given-names>MN</given-names></name>. <article-title>Mitochondrial dysfunction and the inflammatory response</article-title>. <source>Mitochondrion</source>. <year>2013</year> <month>Mar</month>;<volume>13</volume>(<issue>2</issue>):<fpage>106</fpage>–<lpage>18</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.mito.2013.01.003" xlink:type="simple">10.1016/j.mito.2013.01.003</ext-link></comment> <object-id pub-id-type="pmid">23333405</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Waje-Andreassen</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Kråkenes</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ulvestad</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Thomassen</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Myhr</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Aarseth</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>IL-6: An early marker for outcome in acute ischemic stroke</article-title>. <source>Acta Neurol Scand</source>. <year>2005</year>;<volume>111</volume>(<issue>6</issue>):<fpage>360</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1600-0404.2005.00416.x" xlink:type="simple">10.1111/j.1600-0404.2005.00416.x</ext-link></comment> <object-id pub-id-type="pmid">15876336</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spera</surname> <given-names>P a</given-names></name>, <name name-style="western"><surname>Ellison</surname> <given-names>J a</given-names></name>, <name name-style="western"><surname>Feuerstein</surname> <given-names>GZ</given-names></name>, <name name-style="western"><surname>Barone</surname> <given-names>FC</given-names></name>. <article-title>IL-10 reduces rat brain injury following focal stroke</article-title>. <source>Neurosci Lett</source>. <year>1998</year>;<volume>251</volume>(<issue>3</issue>):<fpage>189</fpage>–<lpage>92</lpage>. <object-id pub-id-type="pmid">9726375</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pan</surname> <given-names>H-C</given-names></name>, <name name-style="western"><surname>Kao</surname> <given-names>T-K</given-names></name>, <name name-style="western"><surname>Ou</surname> <given-names>Y-C</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>D-Y</given-names></name>, <name name-style="western"><surname>Yen</surname> <given-names>Y-J</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>C-C</given-names></name>, <etal>et al</etal>. <article-title>Protective effect of docosahexaenoic acid against brain injury in ischemic rats</article-title>. <source>J Nutr Biochem</source>. <year>2009</year> <month>Sep</month>;<volume>20</volume>(<issue>9</issue>):<fpage>715</fpage>–<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jnutbio.2008.06.014" xlink:type="simple">10.1016/j.jnutbio.2008.06.014</ext-link></comment> <object-id pub-id-type="pmid">18805685</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kleinschnitz</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Kraft</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Dreykluft</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hagedorn</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Göbel</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Schuhmann</surname> <given-names>MK</given-names></name>, <etal>et al</etal>. <article-title>Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature</article-title>. <source>Blood</source>. <year>2013</year>;<volume>121</volume>(<issue>4</issue>):<fpage>679</fpage>–<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2012-04-426734" xlink:type="simple">10.1182/blood-2012-04-426734</ext-link></comment> <object-id pub-id-type="pmid">23160472</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bannenberg</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Serhan</surname> <given-names>CN</given-names></name>. <article-title>Specialized pro-resolving lipid mediators in the inflammatory response: An update</article-title>. <source>Biochim Biophys Acta</source>. Elsevier B.V.; <year>2010</year> <month>Dec</month>;<volume>1801</volume>(<issue>12</issue>):<fpage>1260</fpage>–<lpage>73</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbalip.2010.08.002" xlink:type="simple">10.1016/j.bbalip.2010.08.002</ext-link></comment> <object-id pub-id-type="pmid">20708099</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spite</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Clària</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Serhan</surname> <given-names>CN</given-names></name>. <article-title>Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases</article-title>. <source>Cell Metab</source>. <year>2014</year> <month>Jan</month> <day>7</day>;<volume>19</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>36</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cmet.2013.10.006" xlink:type="simple">10.1016/j.cmet.2013.10.006</ext-link></comment> <object-id pub-id-type="pmid">24239568</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref057"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Serhan CN. Resolvins and Protectins : Specialized Pro-Resolving Mediators in Inflammation and Organ Protection : Metabolomics of Catabasis. 2008;1–28.</mixed-citation></ref>
<ref id="pone.0167329.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mukherjee</surname> <given-names>PK</given-names></name>, <name name-style="western"><surname>Marcheselli</surname> <given-names>VL</given-names></name>, <name name-style="western"><surname>Serhan</surname> <given-names>CN</given-names></name>, <name name-style="western"><surname>Bazan</surname> <given-names>NG</given-names></name>. <article-title>Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2004</year> <month>Jun</month> <day>1</day>;<volume>101</volume>(<issue>22</issue>):<fpage>8491</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0402531101" xlink:type="simple">10.1073/pnas.0402531101</ext-link></comment> <object-id pub-id-type="pmid">15152078</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lukiw</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Cui</surname> <given-names>J-G</given-names></name>, <name name-style="western"><surname>Marcheselli</surname> <given-names>VL</given-names></name>, <name name-style="western"><surname>Bodker</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Botkjaer</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gotlinger</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease</article-title>. <source>J Clin Invest</source>. <year>2005</year> <month>Oct</month>;<volume>115</volume>(<issue>10</issue>):<fpage>2774</fpage>–<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI25420" xlink:type="simple">10.1172/JCI25420</ext-link></comment> <object-id pub-id-type="pmid">16151530</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bazan</surname> <given-names>NG</given-names></name>. <article-title>Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer’s disease</article-title>. <source>J Lipid Res</source>. <year>2009</year> <month>Apr</month>;<volume>50</volume> Suppl:<fpage>S400</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1194/jlr.R800068-JLR200" xlink:type="simple">10.1194/jlr.R800068-JLR200</ext-link></comment> <object-id pub-id-type="pmid">19018037</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eady</surname> <given-names>TN</given-names></name>, <name name-style="western"><surname>Khoutorova</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Atkins</surname> <given-names>KD</given-names></name>, <name name-style="western"><surname>Bazan</surname> <given-names>NG</given-names></name>, <name name-style="western"><surname>Belayev</surname> <given-names>L</given-names></name>. <article-title>Docosahexaenoic acid complexed to human albumin in experimental stroke: neuroprotective efficacy with a wide therapeutic window</article-title>. <source>Exp Transl Stroke Med. Experimental &amp; Translational Stroke Medicine</source>; <year>2012</year> <month>Jan</month>;<volume>4</volume>(<issue>1</issue>):<fpage>19</fpage>.</mixed-citation></ref>
<ref id="pone.0167329.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pastor-Clerigues</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Marti-Bonmati</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Milara</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Almudever</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Cortijo</surname> <given-names>J</given-names></name>. <article-title>Anti-inflammatory and anti-fibrotic profile of fish oil emulsions used in parenteral nutrition-associated liver disease</article-title>. <source>PLoS One</source>. <year>2014</year> <month>Jan</month>;<volume>9</volume>(<issue>12</issue>):<fpage>e115404</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0115404" xlink:type="simple">10.1371/journal.pone.0115404</ext-link></comment> <object-id pub-id-type="pmid">25502575</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref063"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sanderson</surname> <given-names>TH</given-names></name>, <name name-style="western"><surname>Reynolds</surname> <given-names>C a</given-names></name>, <name name-style="western"><surname>Kumar</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Przyklenk</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hüttemann</surname> <given-names>M</given-names></name>. <article-title>Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation</article-title>. <source>Mol Neurobiol</source>. <year>2013</year> <month>Feb</month>;<volume>47</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12035-012-8344-z" xlink:type="simple">10.1007/s12035-012-8344-z</ext-link></comment> <object-id pub-id-type="pmid">23011809</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref064"><label>64</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eltzschig</surname> <given-names>HK</given-names></name>, <name name-style="western"><surname>Eckle</surname> <given-names>T</given-names></name>. <article-title>Ischemia and reperfusion—from mechanism to translation</article-title>. <source>Nat Med</source>. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.; <year>2011</year> <month>Jan</month>;<volume>17</volume>(<issue>11</issue>):<fpage>1391</fpage>–<lpage>401</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nm.2507" xlink:type="simple">10.1038/nm.2507</ext-link></comment> <object-id pub-id-type="pmid">22064429</object-id></mixed-citation></ref>
<ref id="pone.0167329.ref065"><label>65</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Molina</surname> <given-names>CA</given-names></name>. <article-title>Reperfusion therapies for acute ischemic stroke: current pharmacological and mechanical approaches</article-title>. <source>Stroke</source>. <year>2011</year> <month>Jan</month>;<volume>42</volume>(1 Suppl):<fpage>S16</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.110.598763" xlink:type="simple">10.1161/STROKEAHA.110.598763</ext-link></comment> <object-id pub-id-type="pmid">21164113</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>